STRO Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (STRO) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $1.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.6% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.